Angliana Chouw, Tiana Milanda, Cynthia Retna Sartika, Marsya Nilam Kirana, Danny Halim, Ahmad Faried
{"title":"Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19.","authors":"Angliana Chouw, Tiana Milanda, Cynthia Retna Sartika, Marsya Nilam Kirana, Danny Halim, Ahmad Faried","doi":"10.1007/s40883-021-00202-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>The COVID-19 disease, which is caused by the novel coronavirus, SARS-CoV-2, has affected the world by increasing the mortality rate in 2020. Currently, there is no definite treatment for COVID-19 patients. Several clinical trials have been proposed to overcome this disease and many are still under investigation. In this review, we will be focusing on the potency of mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. Fever, cough, headache, dizziness, and fatigue are the common clinical manifestations in COVID-19 patients. In mild and severe cases, cytokines are released hyper-actively which causes a cytokine storm leading to acute respiratory distress syndrome (ARDS). In order to maintain the lung microenvironment in COVID-19 patients, MSCs are used as cell-based therapy approaches as they can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote endogenous repair. Besides, MSCs have shown minimal expression of ACE2 or TMPRSS2, and hence, MSCs are free from SARS-CoV-2 infection. Numerous clinical studies have started worldwide and demonstrated that MSCs have great potential for ARDS treatment in COVID-19 patients. Preliminary data have shown that MSCs and MSC-derived secretome appear to be promising in the treatment of COVID-19.</p><p><strong>Lay summary: </strong>The COVID-19 disease is an infection disease which affects the world in 2020. Currently, there is no definite treatment for COVID-19 patients. However, several clinical trials have been proposed to overcome this disease and one of them is using mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. During the infection, cytokines are released hyper-actively which causes a cytokine storm. MSCs play an important role in maintaining the lung microenvironment in COVID-19 patients. They can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote the endogenous repair. Therefore, it is important to explore the clinical trial in the world for treating the COVID-19 disease using MSCs and MSC-derived secretome.</p>","PeriodicalId":20936,"journal":{"name":"Regenerative Engineering and Translational Medicine","volume":"8 1","pages":"43-54"},"PeriodicalIF":2.2000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40883-021-00202-5","citationCount":"20","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regenerative Engineering and Translational Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40883-021-00202-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/3/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 20
Abstract
Abstract: The COVID-19 disease, which is caused by the novel coronavirus, SARS-CoV-2, has affected the world by increasing the mortality rate in 2020. Currently, there is no definite treatment for COVID-19 patients. Several clinical trials have been proposed to overcome this disease and many are still under investigation. In this review, we will be focusing on the potency of mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. Fever, cough, headache, dizziness, and fatigue are the common clinical manifestations in COVID-19 patients. In mild and severe cases, cytokines are released hyper-actively which causes a cytokine storm leading to acute respiratory distress syndrome (ARDS). In order to maintain the lung microenvironment in COVID-19 patients, MSCs are used as cell-based therapy approaches as they can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote endogenous repair. Besides, MSCs have shown minimal expression of ACE2 or TMPRSS2, and hence, MSCs are free from SARS-CoV-2 infection. Numerous clinical studies have started worldwide and demonstrated that MSCs have great potential for ARDS treatment in COVID-19 patients. Preliminary data have shown that MSCs and MSC-derived secretome appear to be promising in the treatment of COVID-19.
Lay summary: The COVID-19 disease is an infection disease which affects the world in 2020. Currently, there is no definite treatment for COVID-19 patients. However, several clinical trials have been proposed to overcome this disease and one of them is using mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. During the infection, cytokines are released hyper-actively which causes a cytokine storm. MSCs play an important role in maintaining the lung microenvironment in COVID-19 patients. They can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote the endogenous repair. Therefore, it is important to explore the clinical trial in the world for treating the COVID-19 disease using MSCs and MSC-derived secretome.
期刊介绍：
Regenerative Engineering is an international journal covering convergence of the disciplines of tissue engineering, advanced materials science, stem cell research, the physical sciences, and areas of developmental biology. This convergence brings exciting opportunities to translate bench-top research into bedside methods, allowing the possibility of moving beyond maintaining or repairing tissues to regenerating them. The journal encourages both top-down engineering approaches and bottom-up strategies integrating materials science with stem cell research and developmental biology. Convergence papers on instructive biomaterials, stimuli-responsive biomaterials, micro- and nano-patterning for regenerative engineering, elastomeric biomaterials, hydrogels for tissue engineering, and rapid prototyping and bioprinting approaches are particularly welcome.
The journal provides a premier, single-blind peer-reviewed forum for the publication of original papers, authoritative reviews, rapid communications, news and views, and opinion papers addressing the most important issues and efforts toward successfully regenerating complex human tissues and organs. All research articles feature a lay abstract highlighting the relevance and future impact for patients, government and other health officials, and members of the general public. Bridging the gap between the lab and the clinic, the journal also serves as a dedicated platform for showcasing translational research that brings basic scientific research and discoveries into clinical methods and therapies, contributing to the improvement of human health care.
Topics covered in Regenerative Engineering and Translational Medicine include:
Advanced materials science for regenerative and biomedical applicationsStem cells for tissue regenerationDrug delivery for tissue regenerationNanomaterials and nanobiotechnology for tissue regenerationStudies combining tissue engineering/regeneration with developmental biologyConvergence research in pre-clinical and clinical phases
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
